The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Aug. 5, 6:23 AM

Slide #23. Genocea Biosciences, Inc. Secondary Offering

Company: Genocea Biosciences, Inc. (NASDAQ:GNCA)
Date announced: 7/29/2015
Shares Offered: 3,850,000
Date of Pricing: 7/30/2015
Price Per Share: $13.00
Secondary Offering Details: Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. As part of this proposed offering, Genocea intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All the shares in the offering will be sold by Genocea. - UPDATED 7/30 - Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the pricing of its public offering of 3,850,000 shares of its common stock at a public offering price of $13.00 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 577,500 shares of common stock at the same price. The offering is expected to close on or about August 4, 2015, subject to satisfaction of customary closing conditions.

Genocea Biosciences is a clinical stage biopharmaceutical company. Co. uses its platform technology called AnTigen Lead Acquisition System (ATLAS), which mimics the human immune response in the laboratory. Using the ATLAS platform, Co. is developing its product candidate, GEN-003, in a phase 1/2a clinical trial to treat patients with herpes simplex virus type-2. Co. is also developing other product candidates, including GEN-004, which is being developed to prevent infections caused by pneumococcus. Co.'s other development programs include GEN-001 under the Chlamydia Prophylaxis program, GEN-002 under the HSV-2 Prophylaxis program, and GEN-005 under research of Malaria Prophylaxis program.
Open the GNCA Page at The Online Investor »

Company Name:  Genocea Biosciences Inc
Website:  www.genocea.com
Sector:  Biotechnology
Number of ETFs Holding GNCA:  12
Total Market Value Held by ETFs:  $7.48M
Total Market Capitalization:  $314.00M
% of Market Cap. Held by ETFs:  2.38%
 

Open the GNCA Page at The Online Investor (in a new window) »

August 5, 2015    6:23 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
91st percentile
(ranked higher than approx. 91% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.